DA32 Life Science Tech Acquisition Corp.

Status: Liquidated
U=S
IPO Proceeds, $M $200.00M
IPO Date Jul 28, 2021
CEO Steve Kafka
Left Lead JP Morgan
IPO Cash in Trust 100.0%
SPAC Tenor 24 months
IPO Sector Healthcare

Life sciences

IPO Geography Global
Target Company N/A
Deal Announced N/A
Deal Size, $M TBD
Deal Sector TBD
Deal Geography TBD
SEC Filings www.sec.gov
Approval Vote TBD
Amendment Vote TBD
Closing Date Jul 31, 2023
DALS

Sign up for Free Trial

No credit card required

Sign in for more on DA32 Life Science Tech Acquisition Corp.:

  • Structure and cap table
  • 8 directors & officers
  • 5 filings and events
  • 2 underwriters
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Steve Kafka 51 Chief Executive Officer and Director
Christopher Wolfe 41 Chief Financial Officer and Secretary
Andrew ElBardissi 39 Director
Keith Crandell 61 Director
Mara Aspinall 58 Director
Kevin Hrusovsky 60 Director
Angela Lai 50 Director
Nick Roelofs 63 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
JP Morgan Joint BR 11,500,000 units
Cowen Joint BR 8,500,000
20,000,000 units
Up-Front UW fee 2.00 %
Deferred UW fee 3.50 %

Sign in to view more advisor data.

Filings

Sign in to view 5 filings.

Shareholders

Sign in to view shareholders 13F filing data.